1
|
Planchard D, Feng PH, Karaseva N, Kim SW, Kim TM, Lee CK, Poltoratskiy A, Yanagitani N, Marshall R, Huang X, Howarth P, Jänne PA, Kobayashi K. Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. ESMO Open 2021; 6:100271. [PMID: 34543864 PMCID: PMC8453202 DOI: 10.1016/j.esmoop.2021.100271] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 08/11/2021] [Accepted: 08/21/2021] [Indexed: 11/25/2022] Open
Abstract
Background The phase III FLAURA2 (NCT04035486) study will evaluate efficacy and safety of first-line osimertinib with platinum–pemetrexed chemotherapy versus osimertinib monotherapy in epidermal growth factor receptor mutation-positive (EGFRm) advanced/metastatic non-small-cell lung cancer (NSCLC). The safety run-in, reported here, assessed the safety and tolerability of osimertinib with chemotherapy prior to the randomized phase III evaluation. Patients and methods Patients (≥18 years; Japan: ≥20 years) with EGFRm locally advanced/metastatic NSCLC received oral osimertinib 80 mg once daily (QD), with either intravenous (IV) cisplatin 75 mg/m2 or IV carboplatin target area under the curve 5, plus pemetrexed 500 mg/m2 every 3 weeks (Q3W) for four cycles. Maintenance was osimertinib 80 mg QD with pemetrexed 500 mg/m2 Q3W until progression/discontinuation. The primary objective was to evaluate safety and tolerability of the osimertinib–chemotherapy combination. Results Thirty patients (15 per group) received treatment [Asian, 73%; female, 63%; median age (range) 61 (45-84) years]. Adverse events (AEs) were reported by 27 patients (90%): osimertinib–carboplatin–pemetrexed, 100%; osimertinib–cisplatin–pemetrexed, 80%. Most common AEs were constipation (60%) with osimertinib–carboplatin–pemetrexed and nausea (60%) with osimertinib–cisplatin–pemetrexed. In both groups, 20% of patients reported serious AEs. No specific pattern of AEs leading to dose modifications/discontinuations was observed; one patient discontinued all study treatments including osimertinib due to pneumonitis (study-specific discontinuation criterion). Hematologic toxicities were as expected and manageable. Conclusions Osimertinib–chemotherapy combination had a manageable safety and tolerability profile in EGFRm advanced/metastatic NSCLC, supporting further assessment in the FLAURA2 randomized phase. FLAURA2 aims to assess efficacy and safety of first-line osimertinib with platinum–pemetrexed in EGFRm advanced NSCLC. In the FLAURA2 safety run-in period, 30 patients received osimertinib and pemetrexed with carboplatin or cisplatin. Most common AEs were constipation and nausea; no AE patterns leading to dose modifications/discontinuations were observed. The FLAURA2 safety run-in study showed that the safety profile of this combination was as expected and manageable.
Collapse
Affiliation(s)
- D Planchard
- Institut Gustave Roussy, Department of Medical Oncology, Thoracic Oncology Unit, Villejuif, France.
| | - P-H Feng
- Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan
| | - N Karaseva
- City Clinical Oncology Dispensary, St. Petersburg, Russia
| | - S-W Kim
- Asan Medical Center, Seoul, Republic of Korea
| | - T M Kim
- Seoul National University Hospital, Seoul, Republic of Korea
| | - C K Lee
- Clinical Research Unit, Division of Cancer Services, St. George Hospital, Kogarah, Australia
| | - A Poltoratskiy
- Department of Clinical Trials, Petrov Research Institute of Oncology, St. Petersburg, Russia
| | - N Yanagitani
- Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan
| | | | | | | | - P A Jänne
- Dana-Farber Cancer Institute, Boston, USA
| | - K Kobayashi
- Department of Respiratory Medicine, Saitama Medical School International Medical Center, Saitama, Japan
| |
Collapse
|
2
|
Kim SW, Planchard D, Feng PH, Karaseva N, Kim T, Lee C, Poltoratskiy A, Yanagitani N, Powar S, Huang X, Howarth P, Jänne P, Kobayashi K. 366MO Osimertinib plus platinum/pemetrexed in newly diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.359] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
3
|
Planchard D, Feng PH, Karaseva N, Kim SW, Kim T, Lee C, Poltoratskiy A, Yanagitani N, Powar S, Huang X, Howarth P, Jänne P, Kobayashi K. 1401P Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1715] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
4
|
Karaseva N, Gantsevich M, Obzhirov A, Shakirov R, Starovoitov A, Smirnov R, Malakhov V. Correlation of the siboglinid (Annelida: Siboglinidae) distribution to higher concentrations of hydrocarbons in the Sea of Okhotsk. Mar Pollut Bull 2020; 158:111448. [PMID: 32753224 DOI: 10.1016/j.marpolbul.2020.111448] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 07/05/2020] [Accepted: 07/06/2020] [Indexed: 05/28/2023]
Abstract
Siboglinids are a characteristic feature of reducing environments. More than 75% of all siboglinids were found in the Sea of Okhotsk at a depth of less than 400 m, while some species are known to inhabit the abyssal depth in other regions. Among the six species of siboglinids encountered in the Sea of Okhotsk, only two are widespread: Siboglinum caulleryi and Oligobrachia dogieli. A significant number of all findings belong to the area where, according to geological data, the methane concentration varies between 0.22 and 4.46*109 nmol/kg. There is a vast territory in the central part of the Sea of Okhotsk that is not inhabited by siboglinids and is characterized by minimum methane concentration values. Thus, data on the Sea of Okhotsk indicate that siboglinids are related to sites of methane seepage.
Collapse
Affiliation(s)
- N Karaseva
- Department of Biology, Lomonosov Moscow State University, Leninskie gory 1 bld 12, 119234 Moscow, Russia.
| | - M Gantsevich
- Department of Biology, Lomonosov Moscow State University, Leninskie gory 1 bld 12, 119234 Moscow, Russia
| | - A Obzhirov
- V.I. Il'ichev Pacific Oceanological Institute, FEB RAS, Baltijskaya 43, 690041 Vladivostok, Russia
| | - R Shakirov
- V.I. Il'ichev Pacific Oceanological Institute, FEB RAS, Baltijskaya 43, 690041 Vladivostok, Russia
| | - A Starovoitov
- Department of Geology, Lomonosov Moscow State University, Leninskie gory GSP-1, 119234 Moscow, Russia
| | - R Smirnov
- Zoological Institute, Russian Academy of Sciences, Universitetskaya nab. 1, 199034 St. Petersburg, Russia
| | - V Malakhov
- Department of Biology, Lomonosov Moscow State University, Leninskie gory 1 bld 12, 119234 Moscow, Russia
| |
Collapse
|
5
|
Mansfield AS, Każarnowicz A, Karaseva N, Sánchez A, De Boer R, Andric Z, Reck M, Atagi S, Lee JS, Garassino M, Liu SV, Horn L, Wen X, Quach C, Yu W, Kabbinavar F, Lam S, Morris S, Califano R. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Ann Oncol 2019; 31:310-317. [PMID: 31959349 DOI: 10.1016/j.annonc.2019.10.021] [Citation(s) in RCA: 93] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2019] [Revised: 09/27/2019] [Accepted: 10/20/2019] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND The addition of atezolizumab to carboplatin and etoposide (CP/ET) significantly improved progression-free and overall survival for patients with extensive-stage small-cell lung cancer (ES-SCLC) in the IMpower133 study (NCT02763579). We have evaluated adverse events (AEs) and patient-reported outcomes in IMpower133 to assess the benefit-risk profile of this regimen. PATIENTS AND METHODS Patients received four 21-day cycles of CP/ET plus intravenous atezolizumab 1200 mg or placebo (induction phase), followed by atezolizumab or placebo (maintenance phase) until progression or loss of benefit. AEs were assessed and patient-reported outcomes were evaluated every 3 weeks during treatment using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (QLQ-C30) and QLQ-LC13. RESULTS Overall, 394 patients were assessable for safety in the induction phase and 318 in the maintenance phase. The frequency of AEs, grade 3-4 AEs, and serious AEs was similar between arms in both phases. Immune-related AEs were more frequent in the atezolizumab arm during both induction (28% versus 17%; leading to atezolizumab/placebo interruption 9% versus 5%, leading to withdrawal 4% versus 0%) and maintenance (26% versus 15%; leading to atezolizumab/placebo interruption, 3% versus 2%, leading to withdrawal 1% versus 1%), most commonly rash (induction 11% versus 9%, maintenance 14% versus 4%), and hypothyroidism (induction 4.0% versus 0%, maintenance 10% versus 1%). Changes in patient-reported treatment-related symptoms commonly associated with quality of life impairment were generally similar during induction and most of the maintenance phase. Patient-reported function and health-related quality of life (HRQoL) improved in both arms after initiating treatment, with more pronounced and persistent HRQoL improvements in the atezolizumab arm. CONCLUSIONS In patients with ES-SCLC, atezolizumab plus CP/ET has a comparable safety profile to placebo plus CP/ET, and the addition of atezolizumab did not adversely impact patient-reported HRQoL. These data demonstrate the positive benefit-risk profile of first-line atezolizumab plus CP/ET in ES-SCLC and further support this regimen as a new standard of care in this setting. CLINICAL TRIALS NUMBER NCT02763579.
Collapse
Affiliation(s)
- A S Mansfield
- Division of Medical Oncology, Mayo Clinic, Rochester, USA.
| | - A Każarnowicz
- Department of Oncology, Tuberculosis and Lung Disease Hospital, Olsztyn, Poland
| | - N Karaseva
- City Clinical Oncology Dispensary, St Petersburg, Russia
| | - A Sánchez
- Department of Medical Oncology, Hospital Universitario "Virgen del Rocio", Seville, Spain
| | - R De Boer
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - Z Andric
- Department of Medical Oncology, University Hospital Medical Center Bezanijska Kosa, Belgrade, Serbia
| | - M Reck
- Department of Thoracic Oncology, German Center for Lung Research (DZL), Großhansdorf, Germany
| | - S Atagi
- Department of Thoracic Oncology, Kinki-Chuo Chest Medical Center, Osaka, Japan
| | - J-S Lee
- Division of Hematology-Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
| | - M Garassino
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S V Liu
- Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA
| | - L Horn
- Thoracic Oncology Program, Vanderbilt University Medical Center, Nashville, USA
| | - X Wen
- Product Development Oncology, Genentech, Inc., South San Francisco, USA
| | - C Quach
- Product Development Oncology, Genentech, Inc., South San Francisco, USA
| | - W Yu
- Biometrics, Genentech, Inc., South San Francisco, USA
| | - F Kabbinavar
- Product Development Oncology, Genentech, Inc., South San Francisco, USA
| | - S Lam
- Product Development Oncology, Genentech, Inc., South San Francisco, USA
| | - S Morris
- Global PD Medical Affairs (Oncology), F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - R Califano
- Department of Medical Oncology, The Christie NHS Foundation Trust, and Division of Cancer Sciences, University of Manchester, Manchester, UK
| |
Collapse
|
6
|
Califano R, Każarnowicz A, Karaseva N, Sánchez A, Liu S, Horn L, Quach C, Yu W, Kabbinavar F, Lam S, Mansfield A. IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy486] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Imyanitov E, Mitiushkina N, Tiurin V, Iyevleva A, Holmatov M, Filippova E, Moiseyenko F, Levchenko N, Odintsova S, Lozhkina A, Togo A, Karaseva N, Moiseyenko V, Orlov S. Lung cancers carrying distinct ALK fusion variants demonstrate similar responsiveness to ALK tyrosine kinase inhibitors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Garon E, Ciuleanu T, Arrieta O, Prabhash K, Syrigos K, Göksel T, Park K, Kowalyszyn R, Pikiel J, Lewanski C, Thomas M, Dakhil S, Kim J, Karaseva N, Yurasov S, Zimmermann A, Carter GC, Reck M, Cappuzzo F, Perol M. Quality of Life (Qol) Results from the Phase 3 Revel Study of Ramucirumab + Docetaxel (Ram + Dtx) Versus Placebo + Docetaxel (Pl + Dtx) in Advanced/Metastatic Nsclc Patients (Pts) with Progression After Platinum Based Chemotherapy. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.45] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Ready N, Potti A, Karaseva N, Orlov S, Luft A, Popovych O, Liu PY, Holmlund JT, Wood BA, Leopold L. AT-101 or placebo (P) with docetaxel (D) in second-line NSCLC with gene signature biomarker development. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3577] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3577 Background: AT-101 inhibits the Bcl-2 protein family (Bcl-2, Bcl-xL, Mcl-1, Bcl-W) with broad preclinical activity including synergy with D. Methods: We conducted a randomized, double-blind, P-controlled phase 2 study. Patients had received 1 prior chemotherapy regimen for advanced NSCLC. Patients received AT-101 (40 mg b.i.d. days 1–3) or P with D (75 mg/m2 day 1) Q 21 days. Primary endpoint was progression-free survival (PFS) by independent review (IR). Secondary endpoints were overall survival (OS) and investigator determined PFS. 102 patients were planned for 70 events (80% power, HR 0.6, 1-sided alpha 0.1). A biomarker of AT-101 activity was developed by treating 55 NSCLC cell lines with AT-101 and using the corresponding gene expression data to identify a genomic predictor of sensitivity to AT-101. Results: 106 patients were randomized. Baseline factors were balanced. Median OS for patients on AT-101+D was 7.3 months versus 5.6 months for P + D arm (HR 0.60, p = 0.05). The median investigator determined PFS was 12.6 weeks and 10.7 weeks for AT-101+D and P+D arms respectively (HR 1.0, p = 0.49); IR is ongoing. Common adverse events were fatigue (18%), anemia (18%), and dyspnea (18%). Grade 1/2 headaches occurred more frequently in the AT-101 arm. Analysis of gene expression data by Bayesian regression revealed a robust 500 gene predictor of sensitivity to AT-101 that was cross validated in a leave one out analysis and in an independent cohort of 32 NSCLC cell lines. Validation of the predictor in patient samples from the trial is ongoing. Conclusions: In this phase II trial AT-101, an oral pan Bcl-2 family inhibitor, had favorable OS compared to placebo when combined with docetaxel in previously treated NSCLC and was well tolerated. A genomic predictor of AT-101 sensitivity is likely to enrich for responders and identify novel therapeutic combinations for future [Table: see text]
Collapse
Affiliation(s)
- N. Ready
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - A. Potti
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - N. Karaseva
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - S. Orlov
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - A. Luft
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - O. Popovych
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - P. Y. Liu
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - J. T. Holmlund
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - B. A. Wood
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - L. Leopold
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| |
Collapse
|
10
|
Bogdanova N, Karaseva N, Ognerubov N, Golubeva O, Weiden P. Paclitaxel injectable emulsion: Phase 2a study of weekly administration in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7133] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- N. Bogdanova
- Hertzen Research Institute of Oncology, Moscow, Russian Federation; St. Petersburg Oncology Center, St. Petersburg, Russian Federation; Voronezh Burdenko Medical Academy, Voronezh, Russian Federation; PSI Pharma Support Intl, St. Petersburg, Russian Federation; Sonus Pharmaceticals, Bothell, WA
| | - N. Karaseva
- Hertzen Research Institute of Oncology, Moscow, Russian Federation; St. Petersburg Oncology Center, St. Petersburg, Russian Federation; Voronezh Burdenko Medical Academy, Voronezh, Russian Federation; PSI Pharma Support Intl, St. Petersburg, Russian Federation; Sonus Pharmaceticals, Bothell, WA
| | - N. Ognerubov
- Hertzen Research Institute of Oncology, Moscow, Russian Federation; St. Petersburg Oncology Center, St. Petersburg, Russian Federation; Voronezh Burdenko Medical Academy, Voronezh, Russian Federation; PSI Pharma Support Intl, St. Petersburg, Russian Federation; Sonus Pharmaceticals, Bothell, WA
| | - O. Golubeva
- Hertzen Research Institute of Oncology, Moscow, Russian Federation; St. Petersburg Oncology Center, St. Petersburg, Russian Federation; Voronezh Burdenko Medical Academy, Voronezh, Russian Federation; PSI Pharma Support Intl, St. Petersburg, Russian Federation; Sonus Pharmaceticals, Bothell, WA
| | - P. Weiden
- Hertzen Research Institute of Oncology, Moscow, Russian Federation; St. Petersburg Oncology Center, St. Petersburg, Russian Federation; Voronezh Burdenko Medical Academy, Voronezh, Russian Federation; PSI Pharma Support Intl, St. Petersburg, Russian Federation; Sonus Pharmaceticals, Bothell, WA
| |
Collapse
|